Resources

This report provides a summary of the Midlands & East Hepatitis C Educational Event held by HCV Action and NHS England in Nottingham on Friday 10th February 2017.

This report, produced by IMS Health and commissioned by the Association of the British Pharmaceutical Industry (ABPI), provides information related to the uptake of Direct Acting Antiviral treatments (DAAs) over the last five years, to June 2016. The intention of the report is to benchmark the UK – in relation to patient access to these medicines – compared with other European countries. It finds that there have been significant variances in the ability of patients to access these medicines.

These Scottish guidelines, updated in January 2016, provide expert guidance to Health Boards, Area Drug and Therapeutics Committees, and treating clinicians on the efficacy of available treatments for hepatitis C. They also act as a clinical reference source for NHS National Procurement to produce rankings on cost-effectiveness. Development of the guidance was a collaboration between Scotland's viral hepatitis clinical leads and MCN co-ordinators network, National Services Scotland, and Healthcare Improvement Scotland.

On 13th December 2016, HCV Action and Public Health England (PHE) staged a hepatitis C good practice roadshow in Manchester. The event was designed to showcase and share best practice in the prevention, diagnosis, testing and treatment of hepatitis C, and identify specific issues and potential solutions for tackling hepatitis C in Manchester and the wider north west region.